Company Encyclopedia
View More
name
Mediwound
MDWD.US
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd.
4.514 T
MDWD.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking80/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-48.83%E
    • Profit Margin-98.43%E
    • Gross Margin16.50%D
  • Growth ScoreB
    • Revenue YoY6.15%C
    • Net Profit YoY26.57%B
    • Total Assets YoY26.35%A
    • Net Assets YoY46.51%A
  • Cash ScoreC
    • Cash Flow Margin-101.59%D
    • OCF YoY6.15%C
  • Operating ScoreD
    • Turnover0.25D
  • Debt ScoreC
    • Gearing Ratio46.88%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Alliance Global Partners Reaffirms Their Buy Rating on Mediwound (MDWD)

    Alliance Global Partners has reaffirmed their Buy rating on Mediwound (MDWD) with a price target of $25.00. Additionally, Oppenheimer's Jeff Jones also issued a Buy rating on November 21. However, TR | OpenAI reiterated a Hold rating on November 22.

    Tip Ranks·
    US
    MDWD
    +1.52%
    Tip Ranks·
    US
    MDWD
    +1.52%

    The MediWound Ltd. (NASDAQ:MDWD) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

    MediWound Ltd. (NASDAQ:MDWD) released its Q3 results, showing a 6.5% share drop and revenues of $5.4m, missing forecasts by 17%. However, per-share losses were 70% smaller than expected. Analysts forecast 2026 revenues at $28.8m, a 38% increase, with losses at $2.48 per share. Despite revenue downgrades, the consensus price target remains $31.50, indicating no major valuation change. MediWound is expected to grow faster than the industry, with 29% annualized growth until 2026, compared to the industry's 9.5%.

    Simplywall·
    US
    MDWD
    +1.52%
    Simplywall·
    US
    MDWD
    +1.52%

    MediWound: Strong Financial Health and Market Opportunities Drive Buy Rating

    Maxim Group analyst Michael Okunewitch maintains a Buy rating on MediWound due to strong financial health and market opportunities. The company has a solid cash position to sustain operations through 2028 and forecasts steady revenue growth for 2025. Strategic advancements and high demand for products enhance growth prospects. Oppenheimer also maintains a Buy rating with a $34.00 price target.

    Tip Ranks·
    US
    MDWD
    +1.52%
    Tip Ranks·
    US
    MDWD
    +1.52%

    MediWound (NASDAQ:MDWD) Upgraded at Wall Street Zen

    Wall Street Zen upgraded MediWound (NASDAQ:MDWD) from a "sell" to "hold" rating. Other analysts have varied opinions, with some maintaining a "sell" and others a "buy" rating. The stock has a "Moderate Buy" consensus with a target price of $33.50. MediWound's recent earnings beat expectations, and institutional investors have increased their positions in the company. Despite the "Moderate Buy" rating, top analysts suggest better investment options than MediWound.

    Market Beat·
    US
    MDWD
    +1.52%
    Market Beat·
    US
    MDWD
    +1.52%

    MediWound (NASDAQ:MDWD) Announces Earnings Results

    MediWound reported quarterly earnings with an EPS of ($0.24), surpassing analysts' expectations of ($0.81). Despite a negative net margin of 142.18% and return on equity of 96.71%, the stock opened at $17.71. Institutional investors hold 46.83% of the stock. Analysts have a consensus rating of 'Moderate Buy' with a target price of $32.25.

    Market Beat·
    US
    MDWD
    +1.52%
    Market Beat·
    US
    MDWD
    +1.52%
    © 2025 Longbridge｜Disclaimer